Trials / Active Not Recruiting
Active Not RecruitingNCT05229497
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
A Phase Ib/II Study of AK112#PD-1/VEGF Bispecific Antibody# in Combination With AK117#Anti-CD47 Antibody# in Advanced Malignant Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 154 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | IV infusion,Specified dose on specified days |
| DRUG | AK117 | IV infusion,Specified dose on specified days |
| DRUG | Carboplatin | IV infusion,Specified dose on specified days |
| DRUG | Cisplatin | IV infusion,Specified dose on specified days |
| DRUG | 5-Fluorouracil | IV infusion,Specified dose on specified days |
| DRUG | Gemcitabine | IV infusion,Specified dose on specified days |
Timeline
- Start date
- 2022-05-04
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2022-02-08
- Last updated
- 2026-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05229497. Inclusion in this directory is not an endorsement.